UroGen Pharma Cash Flow Statement
NASDAQ: URGNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
36.83-0.15 (-0.41%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
UroGen Pharma free cash flow
In fiscal 2025, UroGen Pharma generated -$162.4 million of operating cash flow and spent $289,000 on capital expenditures. That left free cash flow of -$162.7 million, a free-cash-flow margin of -148.2% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
UroGen Pharma cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -153.49M | -126.87M | -102.24M | -109.78M | -110.82M | -128.48M | -105.15M | -75.66M | -20.00M | -1.94M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 307.00K | 329.00K | 802.00K | 924.00K | 831.00K | 416.00K | 300.00K | 400.00K | 200.00K | 200.00K |
| Stock-Based Compensation | 11.96M | 13.11M | 9.34M | 10.58M | 23.11M | 28.02M | 29.97M | 30.64M | 6.30M | 1.97M |
| Change in Working Capital | -25.56M | 3.92M | 888.00K | -4.69M | -9.65M | -12.59M | 2.53M | 4.19M | 2.49M | 1.03M |
| Operating Cash Flow | -162.44M | -96.77M | -76.38M | -87.56M | -84.89M | -105.89M | -71.02M | -37.33M | -9.57M | 4.19M |
| Capital Expenditures | -289.00K | -295.00K | -194.00K | -254.00K | -752.00K | -1.22M | -325.00K | -560.00K | -271.00K | -695.00K |
| Investing Cash Flow | 61.56M | -20.61M | -953.00K | 1.06M | 4.07M | 93.24M | -145.59M | 35.29M | -36.28M | -719.00K |
| Debt Issued | 0 | 24.49M | 0 | 95.78M | 0 | — | — | — | — | — |
| Financing Cash Flow | 39.92M | 194.62M | 116.93M | 97.13M | 72.32M | 16.53M | 165.25M | 66.42M | 61.59M | -9.00K |
| Net Change in Cash | -60.97M | 77.24M | 39.60M | 10.63M | -8.50M | 3.88M | -51.36M | 64.37M | 15.74M | 3.46M |
| Free Cash Flow | -162.73M | -97.06M | -76.57M | -87.81M | -85.64M | -107.10M | -71.34M | -37.89M | -9.84M | 3.49M |
This table shows 10 annual periods of UroGen Pharma's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow URGN's reporting calendar. What is a cash flow statement?